Brian Houck-Loomis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3287594/publications.pdf

Version: 2024-02-01

1040056 1372567 3,464 12 9 10 citations h-index g-index papers 13 13 13 6632 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Simultaneous epitope and transcriptome measurement in single cells. Nature Methods, 2017, 14, 865-868.	19.0	2,124
2	Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. Genome Biology, 2018, 19, 224.	8.8	674
3	Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature, 2021, 599, 679-683.	27.8	183
4	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine, 2019, 25, 1422-1427.	30.7	144
5	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic <i>EGFR</i> -Mutant Lung Cancers. JAMA Oncology, 2020, 6, 1048.	7.1	96
6	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	12.8	68
7	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. Cancer Discovery, 2021, 11, 3028-3047.	9.4	66
8	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. Clinical Cancer Research, 2021, 27, 4066-4076.	7.0	45
9	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	8.2	26
10	Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations Journal of Clinical Oncology, 2019, 37, 4096-4096.	1.6	9
11	Abstract 1387: Tracking minimal residual disease in post-operative cell-free DNA using MSK-ACCESS. , 2019, , .		2
12	Abstract 2516: A bioinformatics framework for high-sensitivity detection and monitoring of oncogenic gene fusions in plasma cfDNA. , 2019, , .		O